MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4391-4396

  Tivnan, Amanda ^a,b   Foley, Niamh H ^a,b   Tracey, Lorraine ^c   Davidoff, Andrew M ^c,d   Stallings, Raymond L ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

miR 184 transfection; Mouse models; Neuroblastoma; Targeted therapeutics

Indexed keywords

MICRORNA; MICRORNA 184; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SCID MOUSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, SCID; MICRORNAS; NEUROBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650249083     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kim VN: Small RNAs: classification, biogenesis, and function. Mol Cells 19(1): 1-15, 2005.
2. Breving K and Esquela-Kerscher A: The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 42(8): 1316-1329, 2009.
3. Garzon R, Calin GA and Croce CM: MicroRNAs in Cancer. Annu Rev Med 60: 167-179, 2009.
4. Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, Schramm A, Eggert A, Mestdagh P, De Preter K, Vandesompele J, Speleman F and Stallings RL: Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q-neuroblastoma. Clin Cancer Res 16(11): 2971-2978, 2010.
5. Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, Kumps C, Schlierf S, De Preter K, Van Roy N, Noguera R, Laureys G, Schramm A, Eggert A, Westermann F, Speleman F and Vandesompele J: MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumours. Oncogene 29(9): 1394-1404, 2010.
6. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A and Berwanger B: MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 122(3): 699-704, 2008.
7. Stallings RL, Foley NH, Bryan K, Buckley PG and Bray I: Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets 14(9): 951-962, 2010.
8. Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L and Pahlman S: A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab Invest 75(5): 659-675, 1996.
9. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, Alcock L, Mestdagh P, Vandesompele J, Speleman F, London WB, McGrady PW, Higgins DG, O'Meara A, O'Sullivan M and Stallings RL: Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 4(11): e7850, 2009.
10. Stallings RL, Howard J, Dunlop A, Mullarkey M, McDermott M, Breatnach F and O'Meara A: Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma? Cancer Genet Cytogenet 140(2): 133-137, 2003.
11. Chen Y and Stallings RL: Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 67(3): 976-83, 2007.
12. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM and Maris JM: A functional screen identifies miR-34a as a candidate neuroblastoma tumour suppressor gene. Mol Cancer Res 6(5): 735-742, 2008.
13. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, Buckley PG, Ryan J, O'Meara A, O'Sullivan M and Stallings RL: MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 9(1): 83, 2010.
14. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, Boldrini R, Donfrancesco A, Federici V, Giacomini P, Peschle C and Fruci D: Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3(5): e2236, 2008.
15. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7): 489-501, 2002.
16. Dickson PV, Hamner B, Ng CY, Hall MM, Zhou J, Hargrove PW, McCarville MB and Davidoff AM: In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J Pediatr Surg 42(7): 1172-1179, 2007.